Recipharm Advanced Bio

Recipharm Advanced Bio was established in 2022 through the merger of three highly successful specialized CDMO entities, bringing together decades of advanced therapy expertise. Recipharm Advanced Bio is a global CDMO with a Center of Excellence focused on nucleic acids in the United States, a viral and viral vector manufacturing hub in Germany, and a center for recombinant proteins and live biotherapeutic products in Portugal. With top-tier process development talent in the industry and deep expertise in xRNA, plasmids, viral vectors, and the microbiome, Recipharm Advanced Bio is advancing next-generation therapies and building capabilities for the future of biomanufacturing.